Biliary Tract Cancers (BTC):
A Clinical Primer for Managed Care Professionals

Expert Faculty:

Shubham Pant, MD
Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Click here for biography

Target Audience
This activity is designed to meet the educational needs of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.

Statement of Need/Program Overview
Gallbladder cancer and bile duct cancer are collectively known as biliary tract cancers (BTCs). BTC is a heterogeneous disease with poor prognosis. It represents a global health issue with high tumor-related mortality.

Precision oncology provides a long-anticipated strategy to improve care, control costs, and reduce waste in cancer care. However, realizing these benefits is subject to overcoming barriers impacting the timeliness of care for patients which may be impeded by operational inefficiencies, limited biomarker testing, and delays in starting targeted treatments. Managed care professionals have a key role in supporting the timely and appropriate treatment of BTCs. This clinical primer can equip managed care professionals with baseline knowledge to navigate treatment decisions and support timely treatment for patients with BTCs.

Educational Objectives
After completing this activity, the participant should be better able to:

Accreditation Information

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Impact Education, LLC. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional continuing Education (IPCE) credit for learning and change.

Physician Continuing Medical Education
Partners designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Partners designates this continuing education activity for 0.50 contact hour (.050 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: JA4008073-9999-25-160-H01-P
Type of Activity: Knowledge

Continuing Nursing Credit
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.50 contact hour.

DISCLOSURE OF CONFLICTS OF INTEREST
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.

Name of Faculty

Reported Financial Relationship
Shubham Pant, MD Consultant/Advisor/Speaker: Ipsen, Novartis, Daiichi Sankyo, Janssen, AskGene Pharma, BPGBio, Jazz Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Alligator Bioscience, Theriva Biosciences, USWorldmeds, Nihon Medi-Physics Co, Ltd, Revolution Medicine, Arcus, BMS, Merck, Pfizer

Research funding (funding to institution): Mirati Therapeutics, Lilly, Novartis, BMS, Boehringer Ingelheim, Janssen, Arcus, Elicio, Ipsen, Zymeworks, Pfizer, ImmunoMET, Immuneering, Amal Therapeutics, Jazz Therapeutics, Revolution medicine

Stock: Telperian

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.